scholarly journals Do hepatic artery infusion pumps cause recurrent pleural effusions?

2020 ◽  
Vol 2020 (8) ◽  
Author(s):  
Emily Ann Harris ◽  
Rafael Garza Castillon ◽  
Priya Bhakta

Abstract Hepatic artery infusion pump chemotherapy (HAIPC) for colorectal liver metastasis (CRLM) is a new technique in the treatment of CRLM, whose side effects are not well studied. Case Report: This paper aims to understand the side effect profile of HAIPC as it relates to recurrent pleural effusions. This is a case report of a 48-year-old male with CRLM being treated with HAIPC, who presents with recurrent pleural effusions found to be benign/transudative after right-side video-assisted thoracoscopic surgery. Discussion: This study suggests that HAIPC causes recurrent sympathetic pleural effusions as a side effect of the perihepatic inflammation of the localized chemotherapy treatment. Furthermore, we question if sympathetic pleural effusions are a prelude to hepatic toxicity from HAIPC. Lastly, this paper aims to guide the differential diagnosis of pleural effusions in the cancer patient being treated with HAIPC.

2019 ◽  
Vol 229 (2) ◽  
pp. 217-219 ◽  
Author(s):  
Ryan J. Ellis ◽  
Peter Angelos ◽  
William R. Jarnagin ◽  
Nancy E. Kemeny ◽  
Ryan P. Merkow

2019 ◽  
Vol 37 (2) ◽  
pp. 333-339
Author(s):  
Changli Peng ◽  
Chunhui Zhou ◽  
Gang Li ◽  
Haiping Li ◽  
Liangrong Shi

AbstractTo evaluate the benefits and risks of hepatic artery infusion (HAI) gemcitabine and floxuridine (FUDR) in patients with nasopharyngeal carcinoma liver metastases. HAI catheter systems were implanted under the guide of digital subtract angiography (DSA) in 16 patients with unresectable nasopharyngeal carcinoma liver metastases. HAI gemcitabine and FUDR in combination with radiotherapy and systemic chemotherapy were delivered. Disease control rate (DCR) of intrahepatic lesions is 100%, objective response rate (ORR) of intrahepatic lesions is 87.5%, including 4 patients (25%) with complete response (CR), 10 patients (62.5%) with partial response (PR) and 2 patients (12.5%) with stable disease (SD). The median overall survival (mOS) was 30 months. There was no significant difference between patients with < 9 intrahepatic lesions and patients with ≥ 9 intrahepatic lesions (31 months vs. 24 months, P = 0.562). Patients without extrahepatic metastases has longer survival than patients with extrahepatic metastases (31 months vs. 17 months, P = 0.005). In all 72 cycles of HAI, the main grade 3/4 toxicities related to HAI include: leukopenia occur in 8 cycles (11.1%), thrombocytopenia in 5 cycles (6.9%), AST/ALT elevation in 12 cycles (16.7). Catheter related complications occurred in 2 patients (12.5%). HAI gemcitabine and FUDR is effective to improve DCR of intrahepatic lesions and prolong mOS for patients with nasopharyngeal carcinoma liver metastases, and is associated with a relative low rate of toxicity.


2021 ◽  
pp. 102977
Author(s):  
Fahmi H. Kakamad ◽  
Razhan K. Ali ◽  
Shvan H. Mohammed ◽  
Hawar A. Sofi Mohammed ◽  
Mohammed Q. Mustafa ◽  
...  

2021 ◽  
Vol 7 ◽  
pp. 32-32
Author(s):  
Marco Mammana ◽  
Giovanni M. Comacchio ◽  
Alessandro Pangoni ◽  
Andrea Zuin ◽  
Samuele Nicotra ◽  
...  

2021 ◽  
Vol 0 ◽  
pp. 0-0
Author(s):  
Marco Mammana ◽  
Giovanni M. Comacchio ◽  
Alessandro Pangoni ◽  
Andrea Zuin ◽  
Samuele Nicotra ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document